LUYE PHARMA (02186.HK) Financial Statements - Balance Sheet/Income Statement/Cash Flow - Longbridge

Quote List Quote List

Event Tracking

Dec24

Green Leaf Pharmaceuticals Authorizes Lunan to Exclusively Commercialize Three Long-Acting Antipsychotic Injectable Products in Mainland China

09:11

Luye Pharma Grants Jiangsu Nanhua and Xin Pharmaceutical Exclusive Rights to Market Long-Acting Injectable Antipsychotic Drugs

09:01

Dec12

Luye Genenno Holding Issued Convertible Preferred Shares to Bluebell Asset

14:31

Dec7

Green Leaf Pharmaceutical's Five New Products Successfully Included in National Health Insurance Directory and Commercial Health Insurance Innovative Drugs Directory

10:44

Dec4

Qilu Pharmaceutical Proactively Lowers Price of Aflibercept to Capture Market Share

12:11

Nov24

Luye Pharmaceutical's New Drug LY03017 Receives FDA Clinical Trial Approval

00:12

Schedules & Filings

Schedules

Filings

Aug28

Earning Release(CST)

FY2025 Q2 Earning Release (HKD) Revenue 1.741 B, Net Income 171.23 M, EPS 0.0455

Mar30

Earning Release(CST)

FY2024 Q4 Earning Release (HKD) Revenue 1.589 B, Net Income 44.71 M, EPS 0.0118

Aug28

Earning Release(CST)

FY2024 Q2 Earning Release (HKD) Revenue 1.652 B, Net Income 208.37 M, EPS 0.0553

View More

Stock List

Top Gainers

Top Decliners

Main Board

Symbol

Price

%Chg

Change

View More